You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
2-HOBA for Treatment of Pulmonary Hypertension
SBC: MTI Biotech Incorporated Topic: NHLBIPROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Implantable Microarray Probe for Real-Time Glutamate and GABA Detection
SBC: ALCORIX CO Topic: 105Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
MRI Virtual Pathology of the Prostate: Multi-center multi-vendor application and validation
SBC: QMIS Topic: 102PROJECT SUMMARY The U.S. Preventative Task Force found current ultrasound-based screening methods unreliable, causing unnecessary biopsies and failing to detect clinically significant Prostate Cancer (PCa) in patients with an elevated prostate-specific antigen (PSA). Millions of men in the U.S. alone are currently at elevated risk for PCa, but there are no effective alternatives for screening. Alt ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing an app-based behavioral intervention to help depressed individuals return to work
SBC: INSPIRATION AT WORK INC Topic: 104PROJECT SUMMARY Significance: The overarching goal of this proposal is to develop an intervention to help unemployed individuals with major depressive disorder (MDD) return to work. Individuals who lose their jobs are at risk for MDD and other psychiatric disorders. Because a core feature of MDD is decreased motivation, unemployed individuals with MDD can enter a `vicious cycle' where their depres ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA genome, which can cause seasonal or pandemic flu with high morbidity and significant mortality. Vaccination is the most prevalent prophylactic means for controlling influenza infections. However, an effective vaccine usually takes at least six months to develop. Furthermore, vaccination has limited ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
SBC: Medosome Biotec, LLC Topic: NICHDProject Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Prevention of White Matter Injury in Premature Infants
SBC: Medosome Biotec, LLC Topic: NICHDABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
SBC: NEURODON, LLC Topic: NIANeurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Develop and Commercialize the Bayesian Dose-Response Modeling System and Services
SBC: KS & ASSOCIATES LLC Topic: NIEHSPROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics
SBC: Neurolux, Inc. Topic: 101Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biol ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health